Glorieux et al., 2015 - Google Patents
Uraemic toxins and new methods to control their accumulation: game changers for the concept of dialysis adequacyGlorieux et al., 2015
View HTML- Document ID
- 16258758553106326489
- Author
- Glorieux G
- Tattersall J
- Publication year
- Publication venue
- Clinical kidney journal
External Links
Snippet
The current concept of an adequate dialysis based only on the dialysis process itself is rather limited. We now have considerable knowledge of uraemic toxicity and improved tools for limiting uraemic toxin accumulation. It is time to make use of these. A broader concept of …
- 238000000502 dialysis 0 title abstract description 107
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Glorieux et al. | Uraemic toxins and new methods to control their accumulation: game changers for the concept of dialysis adequacy | |
| Neirynck et al. | An update on uremic toxins | |
| Cozzolino et al. | Cardiovascular disease in dialysis patients | |
| Watanabe et al. | Update on the pharmacokinetics and redox properties of protein-bound uremic toxins | |
| Mutsaers et al. | Chronic kidney disease and fibrosis: the role of uremic retention solutes | |
| Vanholder et al. | A bench to bedside view of uremic toxins | |
| Meert et al. | Prospective evaluation of the change of predialysis protein‐bound uremic solute concentration with postdilution online hemodiafiltration | |
| Stenvinkel | Inflammation in end‐stage renal disease: The hidden enemy | |
| Shimizu et al. | NF-κB plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression, and inhibition of proliferation in proximal tubular cells | |
| Meijers et al. | p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin | |
| Morgera et al. | Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status | |
| Cozzolino et al. | Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study | |
| Lane et al. | Renohepatic crosstalk: does acute kidney injury cause liver dysfunction? | |
| Sandeman et al. | An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis | |
| Jia et al. | Acute effects of hemodiafiltration versus conventional hemodialysis on endothelial function and inflammation: a randomized crossover study | |
| Niwa | Targeting protein-bound uremic toxins in chronic kidney disease | |
| Camacho et al. | Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate | |
| Tamura et al. | Therapeutic potential of low‐density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease | |
| Awdishu et al. | How to optimize drug delivery in renal replacement therapy | |
| Esposito et al. | Modulation of myostatin/hepatocyte growth factor balance by different hemodialysis modalities | |
| Massy et al. | From old uraemic toxins to new uraemic toxins: place of ‘omics’ | |
| Tiong et al. | Effect of a medium cut‐off dialyzer on protein‐bound uremic toxins and mineral metabolism markers in patients on hemodialysis | |
| Hyšpler et al. | Indoxyl sulfate elimination in renal replacement therapy: influence of citrate‐versus acetate‐buffering component during bicarbonate dialysis | |
| Molanaei et al. | Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients | |
| Forni et al. | Extracorporeal renal replacement therapies in the treatment of sepsis: where are we? |